Karl Thiel

1 month ago | fool.com | Karl Thiel |Mary Long |Nick Sciple |Ricky Mulvey

In this podcast, Motley Fool analysts Nick Sciple and Karl Theil join hosts Ricky Mulvey and Mary Long to discuss:Kroger's business results. Why some investors are becoming more pessimistic about Abercrombie & Fitch. A small-cap tobacco company playing in a fast-growing trend. An investor's look at robotics company Intuitive Surgical. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center.

1 month ago | fool.com | Karl Thiel |Mary Long |Ricky Mulvey

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss:How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about Ozempic's and Mounjarno's patent cliffs. The scenarios in which Novo Nordisk and Eli Lilly are actually undervalued. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center.

Mar 9, 2024 | fool.com | Dan Boyd |Jason Moser |Karl Thiel

In this podcast, Motley Fool host Dylan Lewis and analysts Jason Moser and Matt Argersinger discuss:Elon Musk's lawsuit against OpenAI and Sam Altman. Apple putting an end to Project Titan and its automotive ambitions. Earnings updates from Axon and Okta, and a new dividend from Salesforce. Two stocks worth watching: Palo Alto Networks and eBay.

Jan 22, 2024 | fool.com | Karl Thiel |Mary Long

In this podcast, Motley Fool host Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss:Biogen's next shot at an Alzheimer's treatment. Why companies can't "muscle their way" into making new molecules. How Nvidia could change drug development. Moderna's vaccine strategy. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks.